» Articles » PMID: 28232372

Late Effects of Blood and Marrow Transplantation

Overview
Journal Haematologica
Specialty Hematology
Date 2017 Feb 25
PMID 28232372
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Hematopoietic cell transplantation is a curative treatment for a variety of hematologic diseases. Advances in transplantation technology have reduced early transplant-related mortality and expanded application of transplantation to older patients and to a wider variety of diseases. Management of late effects after transplantation is increasingly important for a growing number of long-term survivors that is estimated to be half a million worldwide. Many studies have shown that transplant survivors suffer from significant late effects that adversely affect morbidity, mortality, working status and quality of life. Late effects include diseases of the cardiovascular, pulmonary, and endocrine systems, dysfunction of the thyroid gland, gonads, liver and kidneys, infertility, iron overload, bone diseases, infection, solid cancer, and neuropsychological effects. The leading causes of late mortality include recurrent malignancy, lung diseases, infection, secondary cancers and chronic graft--host disease. The aim of this review is to facilitate better care of adult transplant survivors by summarizing accumulated evidence, new insights, and practical information about individual late effects. Further research is needed to understand the biology of late effects allowing better prevention and treatment strategies to be developed.

Citing Articles

Secondary Esophageal Cancer After Hematopoietic Stem Cell Transplant: An Institutional Case Series.

Singh A, McAllister M, Deeb A, Wang S, Rizza K, Ho V Ann Thorac Surg Short Rep. 2025; 2(3):535-539.

PMID: 39790417 PMC: 11708689. DOI: 10.1016/j.atssr.2024.02.014.


Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management.

Goldenberg M, Lanzkron S, Pecker L Expert Rev Hematol. 2024; 17(12):891-905.

PMID: 39499235 PMC: 11669372. DOI: 10.1080/17474086.2024.2423368.


Umbilical Cord Blood Platelet Lysate Eyedrops for the Treatment of Severe Ocular Surface Disorders in Graft vs. Host Disease Patients: Clinical Study.

Gagliano C, Foti R, Zeppieri M, Maniaci A, Lavalle S, Tancredi G Life (Basel). 2024; 14(10).

PMID: 39459568 PMC: 11509496. DOI: 10.3390/life14101268.


Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantation.

Landspersky T, Stein M, Sacma M, Geuder J, Braitsch K, Riviere J Blood Adv. 2024; 8(20):5400-5414.

PMID: 39159429 PMC: 11526086. DOI: 10.1182/bloodadvances.2024012879.


Significant pituitary siderosis is common in transfusion-dependent sickle cell disease.

Vadivelan A, Doyle E, Carson S, Denton C, Veluswamy S, Hofstra T Blood. 2024; 144(13):1457-1459.

PMID: 39046820 PMC: 11451288. DOI: 10.1182/blood.2024025462.


References
1.
Armenian S, Chemaitilly W, Chen M, Chow E, Duncan C, Jones L . National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. Biol Blood Marrow Transplant. 2016; 23(2):201-210. PMC: 5526451. DOI: 10.1016/j.bbmt.2016.08.019. View

2.
Boeckh M, Leisenring W, Riddell S, Bowden R, Huang M, Myerson D . Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2002; 101(2):407-14. DOI: 10.1182/blood-2002-03-0993. View

3.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

4.
Torres H, McDonald G . How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood. 2016; 128(11):1449-57. PMC: 6033045. DOI: 10.1182/blood-2016-05-718643. View

5.
Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H . Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2006; 44(2):245-9. DOI: 10.1086/509930. View